Consequently, chimeric antigen receptor T-cell therapies targeting B7-H3 have been developed against pediatric solid tumors and there is currently enrollment of patients with recurrent glioblastoma multiforme in a phase I trial (NCT05474378; ref. 19). This evidence concerns the gene CD276 and glioblastoma.